

# Combination immunotherapies: Synergizing the power of the immune system against cancer.

Math Glen\*

Department of Medical Oncology, University of Boston, Boston, USA.

## Introduction

The dawn of immunotherapy has revolutionized the landscape of cancer treatment, offering a novel approach that capitalizes on the body's natural defenses to combat malignant cells. However, the complexity of the immune system and the heterogeneity of tumors often lead to variable responses among patients. Recognizing these challenges, researchers have turned their attention to combination immunotherapies, a strategic approach that seeks to enhance treatment efficacy by targeting multiple facets of the immune response simultaneously. This synergy has the potential to unlock new avenues for treating even the most formidable cancers [1].

Cancer's ability to evade the immune system is multifaceted, involving intricate mechanisms that suppress immune responses or render immune cells ineffective. Single-agent immunotherapies, while promising, may not be sufficient to overcome these hurdles. Combination immunotherapies tackle this issue head-on by engaging different components of the immune system or disrupting multiple evasion pathways, leading to more robust and sustained anti-tumor effects.

**Checkpoint Inhibitor Combinations:** Immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 antibodies, have shown remarkable success in unleashing the immune response against cancer cells. Combining these agents has demonstrated synergistic effects, as they target distinct inhibitory pathways, allowing for more comprehensive immune activation [2].

**Immune modulators and cytokines:** Therapies that modulate the tumor microenvironment and enhance immune cell infiltration, such as immune-activating cytokines (IL-2, IL-12), can be combined with checkpoint inhibitors to create an environment that favors anti-tumor responses.

**Adoptive T-cell Therapy and Vaccines:** Adoptive T-cell therapy, where a patient's T cells are harvested, engineered, and reintroduced to target cancer cells, can be potentiated with cancer vaccines that stimulate the immune system to recognize tumor-specific antigens more effectively.

**Oncolytic viruses and immune checkpoints:** Oncolytic viruses infect and lyse cancer cells, releasing tumor antigens and inducing an immune response. When paired with immune checkpoint inhibitors, the immune response is further amplified due to increased availability of antigens [3].

## Case studies of success

**Melanoma:** The combination of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) has revolutionized melanoma treatment, achieving higher response rates and prolonged survival compared to monotherapies.

**Lung cancer:** In Non-Small Cell Lung Cancer (NSCLC), combining pembrolizumab (anti-PD-1) with chemotherapy has become a standard treatment, demonstrating improved outcomes for a wider patient population [4].

## Challenges and future prospects

Combination immunotherapies present exciting opportunities, but they also come with challenges. Managing potential side effects, optimizing dosing regimens, and identifying the most effective combinations for specific cancer types are areas that require careful consideration. The future holds promise for precision medicine in immunotherapy combinations. As we deepen our understanding of tumor genetics and immune interactions, we can tailor combination approaches based on individual patient profiles, ultimately leading to more personalized and effective treatments [5].

## Conclusion

Combination immunotherapies exemplify the epitome of scientific innovation in the fight against cancer. By exploiting the complexities of the immune system and attacking cancer from multiple angles, these therapies offer renewed hope for patients with previously limited treatment options. As ongoing research uncovers novel synergies and insights, combination immunotherapies stand poised to reshape the landscape of oncology, driving us closer to the day when cancer can be conquered through the collaborative power of the immune system.

## References

1. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. *Nat Rev Cancer*. 2012;12(4):237-51.
2. Khalil DN, Smith EL, Brentjens RJ, et al. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. *Nat Rev Clin Oncol*. 2016;13(5):273-90.

\*Correspondence to: Math Glen, Department of Medical Oncology, University of Boston, Boston, USA, E-mail: [glen@dfci.harvard.edu](mailto:glen@dfci.harvard.edu)

Received: 02-Aug-2023, Manuscript No. AACIR-23-112087; Editor assigned: 04-Aug-2023, Pre QC No. AACIR-23-112087(PQ); Reviewed: 18-Aug-2023, QC No. AACIR-23-112087;

Revised: 22-Aug-2023, Manuscript No. AACIR-23-112087 (R); Published: 29-Aug-2023, DOI: 10.35841/aacir-6.4.157

3. Messenheimer DJ, Jensen SM, Afentoulis ME, et al. Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40. *Clin Cancer Res.* 2017;23(20):6165-77.
4. Zhou B, Liu J, Lin M, et al. Recent advances in immunotherapy, immunoadjuvant, and nanomaterial-based combination immunotherapy. *Coord Chem Rev.* 2021;442:214009.
5. Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. *Nat Rev Drug Discov.* 2019;18(3):197-218.